首页 > 最新文献

Archives of ophthalmology最新文献

英文 中文
Eyebrow tissue expansion: an underappreciated entity in thyroid-associated orbitopathy. 眉组织扩张:甲状腺相关眼病中一个未被充分认识的实体。
Pub Date : 2012-12-01 DOI: 10.1001/archophthalmol.2012.2543
Louis M Savar, Ravi M Menghani, Kelvin K Chong, Helene Chokron Garneau, Robert A Goldberg

Objectives: To report photographic evidence of eyebrow tissue expansion in patients with thyroid-associated orbitopathy (TAO) and to demonstrate consistency in grading through the use of standardized photographs.

Methods: A retrospective cohort study of patients referred for evaluation of TAO in an orbitofacial tertiary care center between January 1, 2000, and December 31, 2010. A grading key was produced with representative views of each of 4 grades (0 [no expansion] to 3 [severe expansion]), corresponding to increasing severity of eyebrow tissue expansion. Photographs of each study patient, including both premorbid and morbid photographs, were retrieved from an electronic medical record system and graded by 6 independent, masked observers using this 4-point system.

Results: Seventy-five patients with TAO were identified for inclusion. The average grade was 0.3 for premorbid eyes and 1.1 for morbid eyes. Intraclass correlation coefficients for the premorbid photographs were 0.705 and 0.632 for the right and left eyes, respectively. Intraclass correlation coefficients for the morbid photographs were 0.921 and 0.916 for the right and left eyes, respectively.

Conclusions: Eyebrow tissue expansion is a common manifestation in TAO. Comparison of premorbid and morbid photographs is a useful means to identify and characterize the extent of brow involvement. The use of a grading key improves the consistency of identifying and grading eyebrow tissue expansion. Recognition of the eyebrow tissue as distinct anatomically in TAO may be crucial to rehabilitation of these patients, which may entail multiple surgical procedures.

目的:报告甲状腺相关性眼窝病(TAO)患者眉组织扩张的照片证据,并通过使用标准化照片证明分级的一致性。方法:对2000年1月1日至2010年12月31日在某眶面三级保健中心接受TAO评估的患者进行回顾性队列研究。根据眉毛组织扩张的严重程度,用4个等级(0[无扩张]至3[严重扩张])中的每一个等级的代表性观点进行评分。从电子病历系统中检索每位研究患者的照片,包括发病前和发病时的照片,并由6名独立的蒙面观察者使用4分制进行评分。结果:纳入了75例TAO患者。病前眼的平均评分为0.3,病后眼的平均评分为1.1。右眼和左眼病变前照片的类内相关系数分别为0.705和0.632。右眼和左眼病态照片的类内相关系数分别为0.921和0.916。结论:眉组织扩张是TAO的常见表现。比较病前和病中照片是一个有用的手段,以确定和表征程度的眉毛受累。使用分级键提高了识别和分级眉毛组织膨胀的一致性。在TAO中,认识到眉毛组织在解剖学上是不同的,这可能对这些患者的康复至关重要,这可能需要多次外科手术。
{"title":"Eyebrow tissue expansion: an underappreciated entity in thyroid-associated orbitopathy.","authors":"Louis M Savar,&nbsp;Ravi M Menghani,&nbsp;Kelvin K Chong,&nbsp;Helene Chokron Garneau,&nbsp;Robert A Goldberg","doi":"10.1001/archophthalmol.2012.2543","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.2543","url":null,"abstract":"<p><strong>Objectives: </strong>To report photographic evidence of eyebrow tissue expansion in patients with thyroid-associated orbitopathy (TAO) and to demonstrate consistency in grading through the use of standardized photographs.</p><p><strong>Methods: </strong>A retrospective cohort study of patients referred for evaluation of TAO in an orbitofacial tertiary care center between January 1, 2000, and December 31, 2010. A grading key was produced with representative views of each of 4 grades (0 [no expansion] to 3 [severe expansion]), corresponding to increasing severity of eyebrow tissue expansion. Photographs of each study patient, including both premorbid and morbid photographs, were retrieved from an electronic medical record system and graded by 6 independent, masked observers using this 4-point system.</p><p><strong>Results: </strong>Seventy-five patients with TAO were identified for inclusion. The average grade was 0.3 for premorbid eyes and 1.1 for morbid eyes. Intraclass correlation coefficients for the premorbid photographs were 0.705 and 0.632 for the right and left eyes, respectively. Intraclass correlation coefficients for the morbid photographs were 0.921 and 0.916 for the right and left eyes, respectively.</p><p><strong>Conclusions: </strong>Eyebrow tissue expansion is a common manifestation in TAO. Comparison of premorbid and morbid photographs is a useful means to identify and characterize the extent of brow involvement. The use of a grading key improves the consistency of identifying and grading eyebrow tissue expansion. Recognition of the eyebrow tissue as distinct anatomically in TAO may be crucial to rehabilitation of these patients, which may entail multiple surgical procedures.</p>","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.2543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31111171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. 接受眼动脉化疗的视网膜母细胞瘤患者的血栓形成。
Pub Date : 2012-12-01 DOI: 10.1001/archophthalmol.2012.2284
Jasmine H Francis, Y Pierre Gobin, Aaron Nagiel, Ira J Dunkel, Nicole Kucine, Brian P Marr, Scott E Brodie, David H Abramson
vea, as in cases 2 and 3 in our series. In addition, on SD-OCT images from case 1, the lesions highly scatter and block OCT signal from penetrating to deeper retinal layers. In cases 2 and 3, conversely, the lesions are finer, are located along a thin portion of the inner fovea, and span the entire foveola. In cases 2 and 3, there is some evidence of partial PVD with vitreofoveal attachment on OCT. Although this OCT appearance occurs as a normal stage of PVD progression, it is possible that the white granules may form secondary to mild, persistent vitreofoveal traction. This is speculation, however, and it remains unclear why the granular opacities form. In summary, we describe SDOCT findings in 3 patients with white dot fovea. In this condition, hyperreflective granular material is visualized in the inner retinal layers of the fovea both clinically as well as on OCT. Darkly pigmented fundi seem to enhance visualization of the white foveal granules. It is unknown what the granules are composed of or what structure of the retina they represent, and further studies are needed to elucidate the pathogenesis, prevalence, and potential risk associations of white dot fovea.
{"title":"Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery.","authors":"Jasmine H Francis,&nbsp;Y Pierre Gobin,&nbsp;Aaron Nagiel,&nbsp;Ira J Dunkel,&nbsp;Nicole Kucine,&nbsp;Brian P Marr,&nbsp;Scott E Brodie,&nbsp;David H Abramson","doi":"10.1001/archophthalmol.2012.2284","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.2284","url":null,"abstract":"vea, as in cases 2 and 3 in our series. In addition, on SD-OCT images from case 1, the lesions highly scatter and block OCT signal from penetrating to deeper retinal layers. In cases 2 and 3, conversely, the lesions are finer, are located along a thin portion of the inner fovea, and span the entire foveola. In cases 2 and 3, there is some evidence of partial PVD with vitreofoveal attachment on OCT. Although this OCT appearance occurs as a normal stage of PVD progression, it is possible that the white granules may form secondary to mild, persistent vitreofoveal traction. This is speculation, however, and it remains unclear why the granular opacities form. In summary, we describe SDOCT findings in 3 patients with white dot fovea. In this condition, hyperreflective granular material is visualized in the inner retinal layers of the fovea both clinically as well as on OCT. Darkly pigmented fundi seem to enhance visualization of the white foveal granules. It is unknown what the granules are composed of or what structure of the retina they represent, and further studies are needed to elucidate the pathogenesis, prevalence, and potential risk associations of white dot fovea.","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.2284","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31111179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. 表皮生长因子受体抑制剂治疗眼眶鳞状细胞癌。
Pub Date : 2012-12-01 DOI: 10.1001/archophthalmol.2012.2515
Tarek El-Sawy, Anita L Sabichi, Jeffrey N Myers, Merrill S Kies, William N William, Bonnie S Glisson, Scott Lippman, Bita Esmaeli
Orbitalandperiorbitalsquamouscell carcinomas (SCCs) are treated with surgicalresectionastheprimarymodality and radiation therapy as adjuvant treatment in patients with perineural invasion or concerns for microscopically positive margins. For advanced cases, extensive surgerysuchasorbitalexenterationmay be needed to fully extirpate the tumor. Orbital exenteration leads to loss of the eye and significant facial disfigurement but has the potential to produce long-term cure. The extensive surgical treatments required for advanced cases of orbital and periorbital SCC entail long periods of general anesthesia and inpatient hospitalization; thus, in patientswithpoorperformancestatus, advanced age, or multiple medical comorbidities, surgery may not be the best option. Several epidermal growth factor receptor(EGFR)inhibitorshaverecently been developed and have shownefficacyintreatmentofnon– small cell lung cancer, pancreatic cancer, colon cancer, and mucosal head and neck squamous cell carcinomas. 1-3 We herein report 2 elderly patients with recurrent advancedorbitalSCCwhoweretreated withEGFRinhibitors—erlotinib,an oral tyrosine kinase inhibitor, and cetuximab,amonoclonalantibody– and had striking initial responses to this treatment. Report of Cases.Case 1. A 90-yearold woman with a history of SCC of the left lateral canthus that had
{"title":"Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.","authors":"Tarek El-Sawy,&nbsp;Anita L Sabichi,&nbsp;Jeffrey N Myers,&nbsp;Merrill S Kies,&nbsp;William N William,&nbsp;Bonnie S Glisson,&nbsp;Scott Lippman,&nbsp;Bita Esmaeli","doi":"10.1001/archophthalmol.2012.2515","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.2515","url":null,"abstract":"Orbitalandperiorbitalsquamouscell carcinomas (SCCs) are treated with surgicalresectionastheprimarymodality and radiation therapy as adjuvant treatment in patients with perineural invasion or concerns for microscopically positive margins. For advanced cases, extensive surgerysuchasorbitalexenterationmay be needed to fully extirpate the tumor. Orbital exenteration leads to loss of the eye and significant facial disfigurement but has the potential to produce long-term cure. The extensive surgical treatments required for advanced cases of orbital and periorbital SCC entail long periods of general anesthesia and inpatient hospitalization; thus, in patientswithpoorperformancestatus, advanced age, or multiple medical comorbidities, surgery may not be the best option. Several epidermal growth factor receptor(EGFR)inhibitorshaverecently been developed and have shownefficacyintreatmentofnon– small cell lung cancer, pancreatic cancer, colon cancer, and mucosal head and neck squamous cell carcinomas. 1-3 We herein report 2 elderly patients with recurrent advancedorbitalSCCwhoweretreated withEGFRinhibitors—erlotinib,an oral tyrosine kinase inhibitor, and cetuximab,amonoclonalantibody– and had striking initial responses to this treatment. Report of Cases.Case 1. A 90-yearold woman with a history of SCC of the left lateral canthus that had","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.2515","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31111180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 37
Nasolacrimal duct obstruction resolution. 鼻泪管阻塞解决。
Pub Date : 2012-12-01 DOI: 10.1001/archophthalmol.2012.3067
Caroline J Macewen
{"title":"Nasolacrimal duct obstruction resolution.","authors":"Caroline J Macewen","doi":"10.1001/archophthalmol.2012.3067","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.3067","url":null,"abstract":"","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.3067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31114963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-decade profile of women in leadership positions at ophthalmic publications. 五十年来在眼科刊物担任领导职务的女性概况。
Pub Date : 2012-11-01 DOI: 10.1001/archophthalmol.2012.2300
Ahmad M Mansour, Carol L Shields, Fadi C Maalouf, Vicky A Massoud, Lama Jurdy, Danny G P Mathysen, Dalida Jaafar, Wagih Aclimandos

Objective: To evaluate the balance between the sexes of published ophthalmic material at the editorial, reviewer, and author levels.

Design: Cross-sectional study of 3 journals, American Journal of Ophthalmology, Archives of Ophthalmology, and Ophthalmology, for 1969, 1979, 1989, 1999, and 2009. The data were compared with ophthalmologist-in-training and physician profile in major contributing states from North America and Europe during the same period.

Results: Of the 3 major ophthalmology journals, none had a female editor-in-chief. For all journals, the proportion of editorial board members who were women increased from 3.3% in 1969 to 18.8% in 2009. For all journals and all years, women composed a higher proportion of first authors (29.2% in 2009) compared with senior authors (22.9% in 2009), reviewers (18.9% in 2009), or assistant editors (12.5% in 2009). There was an abrupt shift toward women after 1989 in first authorship in Ophthalmology (1969, 4.6%; 1979, 5.4%; 1989, 12.3%; and 1999, 20.2%), Archives of Ophthalmology (1969, 6.6%; 1979, 5.1%; 1989, 15.6%; and 1999, 28.6%), and American Journal of Ophthalmology (1969, 5.6%; 1979, 4.2%; 1989, 9.2%; and 1999, 23.9%). There was also an abrupt increase in female senior authorship for American Journal of Ophthalmology after 1989 (1979, 8.5%; 1989, 8.1%; and 1999, 18.3%). The increase in female first authorship during the 5 decades was parallel with the increase in US female physicians.

Conclusions: Women ophthalmologists are authoring publications in increasing numbers that match their prevalence in the academic and overall workforce. However, all editors are men. This discrepancy relates to the relatively younger generation of female ophthalmologists or selection bias, a subject that requires further investigation.

目的:评价已发表的眼科资料在编辑、审稿人和作者层面的性别平衡。设计:对1969年、1979年、1989年、1999年和2009年的《美国眼科学杂志》、《眼科学档案》和《眼科学》3种期刊进行横断面研究。这些数据与同期北美和欧洲主要贡献国家的培训眼科医生和医生资料进行了比较。结果:3大眼科期刊均无女性主编。在所有期刊中,女性编辑委员会成员的比例从1969年的3.3%上升到2009年的18.8%。在所有期刊和年份中,女性占第一作者的比例(2009年为29.2%)高于高级作者(2009年为22.9%)、审稿人(2009年为18.9%)或助理编辑(2009年为12.5%)。1989年之后,《眼科学》的第一作者突然转向女性(1969年,4.6%;1979年,5.4%;1989年,12.3%;和1999年,20.2%),眼科档案(1969年,6.6%;1979年,5.1%;1989年,15.6%;和1999年,28.6%),美国眼科杂志(1969年,5.6%;1979年,4.2%;1989年,9.2%;1999年,23.9%)。1989年之后,《美国眼科杂志》的女性资深作者也突然增加(1979年,8.5%;1989年,8.1%;1999年,18.3%)。在50年里,女性第一作者的增加与美国女医生的增加是平行的。结论:女性眼科医生正在撰写越来越多的出版物,与她们在学术和整体劳动力中的流行程度相匹配。然而,所有的编辑都是男性。这种差异与相对年轻一代的女性眼科医生或选择偏见有关,这一主题需要进一步调查。
{"title":"Five-decade profile of women in leadership positions at ophthalmic publications.","authors":"Ahmad M Mansour,&nbsp;Carol L Shields,&nbsp;Fadi C Maalouf,&nbsp;Vicky A Massoud,&nbsp;Lama Jurdy,&nbsp;Danny G P Mathysen,&nbsp;Dalida Jaafar,&nbsp;Wagih Aclimandos","doi":"10.1001/archophthalmol.2012.2300","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.2300","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the balance between the sexes of published ophthalmic material at the editorial, reviewer, and author levels.</p><p><strong>Design: </strong>Cross-sectional study of 3 journals, American Journal of Ophthalmology, Archives of Ophthalmology, and Ophthalmology, for 1969, 1979, 1989, 1999, and 2009. The data were compared with ophthalmologist-in-training and physician profile in major contributing states from North America and Europe during the same period.</p><p><strong>Results: </strong>Of the 3 major ophthalmology journals, none had a female editor-in-chief. For all journals, the proportion of editorial board members who were women increased from 3.3% in 1969 to 18.8% in 2009. For all journals and all years, women composed a higher proportion of first authors (29.2% in 2009) compared with senior authors (22.9% in 2009), reviewers (18.9% in 2009), or assistant editors (12.5% in 2009). There was an abrupt shift toward women after 1989 in first authorship in Ophthalmology (1969, 4.6%; 1979, 5.4%; 1989, 12.3%; and 1999, 20.2%), Archives of Ophthalmology (1969, 6.6%; 1979, 5.1%; 1989, 15.6%; and 1999, 28.6%), and American Journal of Ophthalmology (1969, 5.6%; 1979, 4.2%; 1989, 9.2%; and 1999, 23.9%). There was also an abrupt increase in female senior authorship for American Journal of Ophthalmology after 1989 (1979, 8.5%; 1989, 8.1%; and 1999, 18.3%). The increase in female first authorship during the 5 decades was parallel with the increase in US female physicians.</p><p><strong>Conclusions: </strong>Women ophthalmologists are authoring publications in increasing numbers that match their prevalence in the academic and overall workforce. However, all editors are men. This discrepancy relates to the relatively younger generation of female ophthalmologists or selection bias, a subject that requires further investigation.</p>","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.2300","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31042344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 41
Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. 醋酸氟西诺酮在常染色体显性遗传的新血管炎性玻璃体视网膜病变中的抑制新生血管形成而非纤维化作用
Pub Date : 2012-11-01 DOI: 10.1001/archophthalmol.2012.1971
Paul S Tlucek, James C Folk, Jason A Orien, Edwin M Stone, Vinit B Mahajan

OBJECTIVE To review the effect of the fluocinolone acetonide implant in subjects with autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), an inherited autoimmune uveitis. METHODS A retrospective case series was assembled from patients with ADNIV who received fluocinolone acetonide implants. Visual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed. RESULTS Nine eyes of 5 related patients with ADNIV with uncontrolled inflammation were reviewed. Follow-up ranged from 21.7 to 56.7 months. Visual acuity at implantation ranged from 20/40 to hand motion. Preoperatively, 8 eyes had vitreous cells (a ninth had diffuse vitreous hemorrhage). Eight eyes had cystoid macular edema, 7 had an epiretinal membrane, and 3 had retinal neovascularization. Following implantation, vitreous cells resolved in all eyes and neovascularization regressed or failed to develop. Central macular thickness improved in 4 eyes. During the postoperative course, however, visual acuity continued to deteriorate, with visual acuity at the most recent examination ranging from 20/60 to no light perception. There was also progressive intraocular fibrosis and phthisis in 1 case. Four eyes underwent cataract surgery. Six of the 7 eyes without previous glaucoma surgery had elevated intraocular pressure at some point, and 3 of these required glaucoma surgery. CONCLUSIONS The fluocinolone acetonide implant may inhibit specific features of ADNIV such as inflammatory cells and neovascularization but does not stabilize long-term vision, retinal thickening, or fibrosis. All eyes in this series required cataract extraction, and more than half required surgical intervention for glaucoma. Further studies may identify additional therapies and any benefit of earlier implantation.

目的探讨氟西诺酮植入治疗常染色体显性遗传性新血管性炎症性玻璃体视网膜病变(ADNIV)的疗效。方法回顾性收集了接受氟西诺酮植入的ADNIV患者的病例系列。我们回顾了ADNIV的视力和特征,包括炎症细胞、新生血管、纤维化和囊样黄斑水肿。结果对5例伴有炎症控制的相关ADNIV患者9只眼进行回顾性分析。随访时间为21.7 - 56.7个月。植入时视力从20/40到手部运动。术前8只眼有玻璃体细胞(1 / 9有弥漫性玻璃体出血)。8只眼出现囊样黄斑水肿,7只眼出现视网膜前膜,3只眼出现视网膜新生血管。植入术后,所有眼的玻璃体细胞溶解,新生血管退化或未形成。4眼中央黄斑厚度改善。然而,在术后过程中,视力继续恶化,最近一次检查的视力从20/60到无光感。1例并发进行性眼内纤维化及肺结核。其中四只眼睛接受了白内障手术。未做过青光眼手术的7只眼睛中,有6只在某一时刻眼压升高,其中3只需要青光眼手术。结论氟西诺酮植入物可能抑制ADNIV的特异性特征,如炎症细胞和新生血管形成,但不能稳定长期视力、视网膜增厚或纤维化。所有的眼睛都需要白内障摘除,超过一半的人需要青光眼手术治疗。进一步的研究可能会确定额外的治疗方法和早期植入的任何益处。
{"title":"Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.","authors":"Paul S Tlucek,&nbsp;James C Folk,&nbsp;Jason A Orien,&nbsp;Edwin M Stone,&nbsp;Vinit B Mahajan","doi":"10.1001/archophthalmol.2012.1971","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.1971","url":null,"abstract":"<p><p>OBJECTIVE To review the effect of the fluocinolone acetonide implant in subjects with autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), an inherited autoimmune uveitis. METHODS A retrospective case series was assembled from patients with ADNIV who received fluocinolone acetonide implants. Visual acuity and features of ADNIV, including inflammatory cells, neovascularization, fibrosis, and cystoid macular edema, were reviewed. RESULTS Nine eyes of 5 related patients with ADNIV with uncontrolled inflammation were reviewed. Follow-up ranged from 21.7 to 56.7 months. Visual acuity at implantation ranged from 20/40 to hand motion. Preoperatively, 8 eyes had vitreous cells (a ninth had diffuse vitreous hemorrhage). Eight eyes had cystoid macular edema, 7 had an epiretinal membrane, and 3 had retinal neovascularization. Following implantation, vitreous cells resolved in all eyes and neovascularization regressed or failed to develop. Central macular thickness improved in 4 eyes. During the postoperative course, however, visual acuity continued to deteriorate, with visual acuity at the most recent examination ranging from 20/60 to no light perception. There was also progressive intraocular fibrosis and phthisis in 1 case. Four eyes underwent cataract surgery. Six of the 7 eyes without previous glaucoma surgery had elevated intraocular pressure at some point, and 3 of these required glaucoma surgery. CONCLUSIONS The fluocinolone acetonide implant may inhibit specific features of ADNIV such as inflammatory cells and neovascularization but does not stabilize long-term vision, retinal thickening, or fibrosis. All eyes in this series required cataract extraction, and more than half required surgical intervention for glaucoma. Further studies may identify additional therapies and any benefit of earlier implantation.</p>","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.1971","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30748996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Projecting the growth of cataract surgery during the next 25 years. 预测未来25年白内障手术的发展。
Pub Date : 2012-11-01 DOI: 10.1001/archophthalmol.2012.838
Wendy V Hatch, Erica de L Campbell, Chaim M Bell, Sherif R El-Defrawy, Robert J Campbell
{"title":"Projecting the growth of cataract surgery during the next 25 years.","authors":"Wendy V Hatch,&nbsp;Erica de L Campbell,&nbsp;Chaim M Bell,&nbsp;Sherif R El-Defrawy,&nbsp;Robert J Campbell","doi":"10.1001/archophthalmol.2012.838","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.838","url":null,"abstract":"","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.838","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31042814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 45
Error in Author's Name in: Intravitreal Bevacizumab for Peripapillary Choroidal Neovascular Membranes. 作者姓名错误:玻璃体内贝伐单抗治疗乳头周围脉络膜新生血管膜。
Pub Date : 2012-11-01 DOI: 10.1001/2013.jamaophthalmol.450
{"title":"Error in Author's Name in: Intravitreal Bevacizumab for Peripapillary Choroidal Neovascular Membranes.","authors":"","doi":"10.1001/2013.jamaophthalmol.450","DOIUrl":"https://doi.org/10.1001/2013.jamaophthalmol.450","url":null,"abstract":"","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamaophthalmol.450","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31494618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chlorpromazine-induced corneal toxicity. 氯丙嗪引起的角膜毒性。
Pub Date : 2012-11-01 DOI: 10.1001/archophthalmol.2012.475
Victor Koh, Wei-Boon Khor, Li Lim
{"title":"Chlorpromazine-induced corneal toxicity.","authors":"Victor Koh,&nbsp;Wei-Boon Khor,&nbsp;Li Lim","doi":"10.1001/archophthalmol.2012.475","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.475","url":null,"abstract":"","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.475","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31042341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma. 视神经脑膜瘤立体定向分割放疗后放射黄斑病变患者对贝伐单抗快速反应后对雷尼单抗的反应。
Pub Date : 2012-11-01 DOI: 10.1001/archophthalmol.2012.1542
Gurjeet Jutley, Olajumoke A Shona, Richard Cheong Leen, Nicholas Lee, Jane M Olver, Sheena M George
{"title":"Response to ranibizumab following tachyphylaxis to bevacizumab in a patient with radiation maculopathy following stereotactic fractionated radiotherapy for optic nerve meningioma.","authors":"Gurjeet Jutley,&nbsp;Olajumoke A Shona,&nbsp;Richard Cheong Leen,&nbsp;Nicholas Lee,&nbsp;Jane M Olver,&nbsp;Sheena M George","doi":"10.1001/archophthalmol.2012.1542","DOIUrl":"https://doi.org/10.1001/archophthalmol.2012.1542","url":null,"abstract":"","PeriodicalId":8303,"journal":{"name":"Archives of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archophthalmol.2012.1542","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31042351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
期刊
Archives of ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1